Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 11.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,962,883 shares of the company's stock after buying an additional 1,083,633 shares during the period. Price T Rowe Associates Inc. MD owned about 16.02% of Replimune Group worth $132,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REPL. Geode Capital Management LLC boosted its holdings in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares during the last quarter. Barclays PLC grew its holdings in shares of Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Replimune Group during the fourth quarter worth $543,000. Swiss National Bank lifted its stake in shares of Replimune Group by 57.4% in the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after buying an additional 37,800 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Replimune Group by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock valued at $2,113,000 after acquiring an additional 11,893 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on REPL shares. BMO Capital Markets upped their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $19.43.

Replimune Group Trading Up 4.0 %

Shares of NASDAQ REPL traded up $0.38 during trading on Friday, reaching $10.02. The stock had a trading volume of 254,549 shares, compared to its average volume of 869,101. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a market cap of $771.84 million, a P/E ratio of -3.26 and a beta of 1.26. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The business's 50-day moving average price is $9.88 and its 200-day moving average price is $11.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.